Seattle startup Lumen Bioscience is working with Google to make drugs using algae

Seattle startup Lumen Bioscience is working with Google to make drugs using algae

Can machine studying assist spur the manufacturing of algae-based biologics? That’s the query new analysis from Seattle biotech startup Lumen Bioscience and Google goals to reply.

The businesses announced a collaboration on Wednesday and launched a new paper that exhibits how a machine learning-based course of helped double spirulina-based protein manufacturing capabilities.

Lumen additionally stated that it obtained a $2 million grant from the Division of Vitality for the analysis, which is led by Lumen’s head of informatics Caitlin Gamble and Google Accelerated Science engineer Drew Bryant, and is backed partially by the Gates Basis.

“The mix of two pioneering improvements — the machine-learning of Google and our spirulina-based therapeutics manufacturing — brings us even nearer to a totally optimized strategy that would have a significant impression on devastating illnesses globally,” Lumen co-founder Jim Roberts stated in a press release.

Roberts added that the analysis paper is “the primary to describe the appliance of AI methods to biologics manufacturing.”

Lumen manufactures proteins in algae. Spirulina acts like slightly bioreactor to produce excessive quantities of candidate therapeutic proteins. The manufacturing system is rather a lot cheaper than the industrial-scale manufacturing services for the human cells usually used to make biologics.

Lumen raised a $16 million Series B round in September. The corporate additionally just lately introduced a joint challenge with the pharma firm Novo Nordisk and an up to $14.5 million challenge with CARB-X, a nonprofit supporting the event of recent antibacterials. As well as, Lumen just lately snagged a virtually $4 million grant from the U.S. Military to develop a possible therapeutic for COVID-19.

The CARB-X project helps growth of a spirulina capsule in opposition to two pathogens that trigger diarrheal illnesses, Campylobacter jejuni and enterotoxigenic E. coli. The corporate at the moment has a part 2 medical trial, supported partially by the Gates Basis, for diarrhea attributable to these micro organism, which kill 1000’s of youngsters worldwide every year.

Lumen final month said it would expand its manufacturing operations to a former bakery in Seattle’s Wallingford neighborhood.

Related posts

Pediatricians’ Campaign To Make Microwaves Safer for Children


New Graphene Face Masks Offer Very High Anti-bacterial Efficiency, Deactivation of Coronaviruses


“Healthy Obesity” Isn’t Healthy – Still at Increased Risk of Diabetes, Heart Diseases, Strokes and Respiratory Diseases